Bioenergetic Alterations After Exenatide Administration

NCT00623545 on ClinicalTrials.gov · last registry update 2015-01-09

A small phase 4 — 28 participants, against a typical 75. The sponsor logged completion for April 2010. Primary outcome, as filed: Change in Energy Intake Measured Before Treatment and at the End of Treatment.

Status: COMPLETED
Phase: P4
Drug: exenatide
Bydureon, Byetta
Sponsor: University of Wisconsin, Madison
Sponsor type: Other
Enrollment: 28
Started: 2008-01
Primary completion: 2010-04 actual

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Change in Energy Intake Measured Before Treatment and at the End of Treatment.

Conditions studied

Healthy

Every field above is taken directly from the registry record. See all detected changes across the class, or the exenatide page for this molecule’s full trial and approval history.